Skip to content
Bored Studies
RecruitingPhase 2

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Maze Therapeutics · NCT06830629

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–68 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
74
US sites recruiting
68
Study start
February 5, 2025
Record last updated
July 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Being studied: MZE829

Conditions: Proteinuric Kidney Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
  • Chronic kidney disease with persistent albuminuria

Key Exclusion Criteria

  • Organ or bone marrow transplantation
  • History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
  • Conditions that may alter drug absorption, e.g., history of bariatric surgery
  • Type I diabetes
  • Pregnant or currently nursing

Other inclusion/exclusion criteria defined in protocol apply.

Recruiting US locations

+ 8 more on the official record.

Study contacts (from the official record)

  • Maze Therapeutics · 650-850-5075 · APOL1info@mazetx.com
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease (NCT06830629) | Bored Studies